Health care providers with H-1B-sponsored visas accounted for 0.97% of physicians in the US in fiscal year 2024.

The FDA sent warning letters to fluoride supplement manufacturers telling them not to promote the products for use in young kids.

Topline data were announced from 2 replicate phase 3 studies evaluating upadacitinib in adults and adolescents with nonsegmental vitiligo.

The greatest rate of treatment persistence in patients with psoriasis following MACE was seen in those receiving biologics vs other treatment types.

Guidelines have been established regarding the definition, diagnosis, and management of persistent chemotherapy-induced alopecia.

The FDA warned consumers about potential serious adverse events linked to radiofrequency microneedling procedures.

Children experiencing the psychological stress of 'new family structure' in first year of life have increased psoriasis risk.

The overall incidence of psoriasis has nearly doubled globally over 3 decades, with further significant increases predicted by 2040.

Developers of biosimilars will no longer be required by the FDA to conduct clinical trials to prove effectiveness.

Long term data were announced from a phase 3 trial evaluating baricitinib in adolescents aged 12 to less than 18 years with severe alopecia areata.

Therapeutic plasma exchange may allow patients with advanced melanoma to overcome immune checkpoint inhibitor resistance, data suggest.

The stillbirth rate among singleton births in the United States from 2016 through 2022 was 6.8 per 1000 births.